ALK and non-small cell lung carcinoma: Several genetic changes, including anaplastic lymphoma kinase (ALK) rearrangements and Kirsten rat sarcoma (KRAS) and epidermal growth factor receptor (EGFR) mutations, have been proven to be prognostic indicators for NSCLC patients.